Ivabradina Kern Pharma

Ivabradine, the active ingredient in Ivabradina Kern Pharma, is a If channel inhibitor presented as a tablet for oral use. It reduces heart rate and is indicated for chronic stable angina and heart failure with reduced ejection fraction in adult patients.

GNH USA supplies Ivabradina Kern Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradina Kern Pharma acts on the cardiac If current to manage conditions related to elevated heart rate.

Chronic stable angina: improves exercise tolerance by lowering heart rate without affecting contractility. Heart failure with reduced ejection fraction: reduces hospitalization risk by maintaining a lower resting heart rate.

Ivabradina Kern Pharma may cause a range of adverse reactions.

Common Side Effects: - Visual disturbances (phosphenes) - Bradycardia - Headache - Dizziness - Fatigue - Nausea

Serious or Rare Side Effects: - Symptomatic hypotension - Severe bradyarrhythmias - Atrioventricular block - Acute coronary syndrome - Allergic skin reactions - Vision loss (rare)

Use of Ivabradina Kern Pharma requires careful clinical assessment.

Cardiac monitoring: baseline and periodic ECG to detect bradycardia. Avoid in severe hepatic impairment: dose adjustment may be needed. Concomitant beta‑blockers: monitor for excessive heart‑rate reduction. Pregnancy and lactation: use only if benefits outweigh risks. Drug interactions: review all concomitant medications. Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Ivabradina Kern Pharma can interact with several medicines that affect heart rate or metabolism.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ivabradine exposure. - Concomitant ivabradine with other heart‑rate‑lowering agents (e.g., digoxin) in uncontrolled settings.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Verapamil or diltiazem: may modestly increase plasma levels. - Antihypertensives: monitor for additive blood‑pressure effects.